헬릭스미스

084990KOSDAQ자연과학 및 공학 연구개발업

65.3 / 100

Reference Date: 2026-06-10

Financial Score25.5 / 40

News Sentiment20.8 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 43.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Helixms is a biotech company established in 1996, specializing in CDMO, clinical CRO, analytical CRO, and H&B (health and beauty) businesses. It operates a state-of-the-art GMP facility compliant with FDA and Korean regulatory standards, and leverages natural-derived material technologies to develop pharmaceuticals and B2B products. The company also focuses on cell and gene therapy production, with extensive experience in global clinical trials and regulatory compliance.

Number of Employees

44people

Average Salary

54.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

1.53Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-0.33Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.62Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼14.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲47.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.2% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 83

Positive
헬릭스미스, 5년 만에 바이오 USA 참가…엔젠시스 글로벌 사업개발 본...
헬릭스미스의 글로벌 바이오 USA 참가로 인해 엔젠시스 관련 글로벌 사업 확장 기회가 확대되어 긍정적 영향 기대.
Positive
헬릭스미스, ‘2026 바이오USA’ 참석…글로벌 파트너링 추진
헬릭스미스의 글로벌 바이오USA 참가는 새로운 파트너십 기회를 창출하여 긍정적인 시장 반응을 기대할 수 있다.
Positive
헬릭스미스 유전자치료제 中서 첫 품목허가
헬릭스미스의 유전자치료제 NL003가 중국에서 첫 품목허가를 받음으로써 중국 시장 진출에 긍정적 영향 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 4,700Won52-week high 9,47052-week low 2,820

1-month return0.0Point

1m -43.71% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15